Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
UCART20x22 by Cellectis for Mantle Cell Lymphoma: Likelihood of Approval
UCART20x22 is under clinical development by Cellectis and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
UCART20x22 by Cellectis for Marginal Zone B-cell Lymphoma: Likelihood of Approval
UCART20x22 is under clinical development by Cellectis and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
UCART20x22 by Cellectis for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
UCART20x22 is under clinical development by Cellectis and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...
UCART20x22 by Cellectis for Follicular Lymphoma: Likelihood of Approval
UCART20x22 is under clinical development by Cellectis and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...